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Background: The goal of this study was to assess a possible dosimetric advantage of intensity modulated
radiotherapy (IMRT) of upper abdominal malignancies compared to three-dimensional conformal radiotherapy
(3DCRT), and to assess the impact of IMRT on acute toxicity.
Methods: Thirty-one unselected consecutive patients with upper abdominal malignancies were treated with
definitive (n =16) or postoperative (n =15) IMRT. Twenty-one patients (67.7%) received concomitant chemotherapy.
3DCRT plans were generated for comparison, and analysis of variance (ANOVA) for repeated measurements was
used to test for significant difference of dosimetric parameters. Acute toxicity was assessed weekly using the
Common Terminology Criteria for Adverse Events (CTCAE) grading scale.
Results: IMRT plans showed a small but statistically significant improvement of the conformity index compared to
3DCRT plans (difference (95% confidence interval), -0.06 (−0.109 to-0.005); p = 0.03). The homogeneity index was
not significantly improved (p = 0.10). A significantly reduced high dose volume on cost of a significantly increased
low dose volume was observed for the kidneys. The acute toxicity appeared to be less than commonly reported for
corresponding patients treated with 3DCRT. No patient developed grade 3 or 4 non-hematological acute toxicity,
and the most common grade 2 toxicity was vomiting (9.7%).
Conclusions: IMRT offers the potential of a clinically relevant dosimetric advantage compared to 3DCRT in terms of
a reduced acute toxicity. Further optimization of the radiotherapy technique and more clinical trials are required
before IMRT is routinely used for upper abdominal malignancies.Introduction
Upper abdominal malignancies represent some of the
most challenging cancers to treat. Although radiation
therapy has an important role in the treatment of upper
abdominal malignancies, delivery of adequate radiation
doses is often limited by radiation sensitive normal
structures in the upper abdomen. These include the
kidneys, small intestine, stomach, liver, and spinal cord.
Intensity modulated radiotherapy (IMRT) offers a more
conformal dose distribution compared to the standard
radiation technique three-dimensional conformal radio-
therapy (3DCRT). IMRT may facilitate a better normal
tissue sparing and dose escalation to these tumors, which* Correspondence: volker.rudat@gmail.com
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reproduction in any medium, provided the orhas the potential to reduce toxicity and to improve local
control [1].
The goal of this study was to assess a possible dosimet-
ric advantage of IMRT compared to 3DCRT, and to assess
the impact of IMRT on acute toxicity. For this purpose,
IMRT and 3DCRT plans were generated for all patients
and parameters of the dose distribution compared. All
patients were treated with IMRT, and the acute toxicity
assessed weekly using the Common Terminology Criteria
for Adverse Events (CTCAE) grading scale.
Patients and methods
IMRT and 3DCRT plans were generated for 31 unselected
consecutive patients with upper abdominal malignancies
who were treated between January 2010 and March 2013.
The diagnoses of the upper abdominal tumors are listed
in Table 1. Virtual simulation using positron emissiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and treatment characteristics
Total dose (Gy) PTV (cm3)
Diagnosis n Mean (range) Mean SD
Pancreatic cancer 8 52.0 (45.0-59.4) 651 285
Cholangiocarcinoma 6 54.9 (50.4-59.4) 274 268
Ampullary and periampullary cancer 4 52.2 (50.4-54.0) 623 391
Retroperitoneal liposarcoma 3 50.4 (50.4-50.4) 2533 724
Gastro-esophageal junction cancer 3 57.3 (55.8-60.0) 362 228
Paraaortal or hepatogastric lymph
node metastases
3 58.7 (56.0-60.0) 305 195
Gastric cancer 2 45.0 1241 255
Gastric malt lymphoma 1 30.0 1493 -
Adrenal gland cancer 1 55.8 1211 -
Abbreviations: PTV planning target volume, SD standard deviation.
Table 2 Dose constraints used in IMRT treatment planning
Organ Volume Dose
Ipsilateral kidney 33% <18 Gy
20% <28 Gy
Contralateral kidney 30% <6 Gy
55% <12 Gy
Bowel Maximum dose 48 Gy
15% <45 Gy
Spinal cord Maximum dose 40 Gy
Liver 60% <30 Gy
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med in 22 of 31 patients (71%), and conventional com-
puted tomography (CT) simulation in nine patients (29%).
All patients were treated using linac-based step and shoot
IMRT. Sixteen of 31 patients (51.6%) received definitive
radiotherapy, and fifteen patients (48.4%) postoperative
radiotherapy. Twenty-one of 31 patients (67.7%) received
concomitant radiochemotherapy using 5-FU, gemcitabine
or cisplatin-based regimen, and 10 patients (32.3%) radio-
therapy alone. Acute toxicity was assessed once weekly
using the Common Terminology Criteria for Adverse
Events (CTCAE) grading scale version 4.0.
Treatment planning
Virtual simulation in supine position was performed
either using positron emission tomography/computed
tomography (Biograph 64 PET/CT, Siemens Health Care,
Germany) with fluorine-18 (FDG) as tracer or non-
contrast computed tomography (Somatom Sensation
Open 20 Slice CT, Siemens Health Care, Germany). Both
the PET/CT and CT were equipped with the same green
lasers, carbon table-tops and positioning devices as used
for the treatment at the linear accelerators. According to
the departmental protocol a CT slice thickness of 3 mm
was used for the PET/CT simulation and 5 mm for
conventional CT-simulation. The isocenter was defined
using the CT simulation software Coherence Dosimetrist
(Siemens Medical, Germany), and target volumes (PTV and
organs at risk) using the software Coherence Oncologist
(Siemens Medical, Germany). The IMRT and 3DCRT plans
were generated using the treatment planning system XIO
4.4 (CMS, Inc. of St. Louis, Mo, USA). Siemens Oncor
Anvantgarde linear accelerators with a 160-multileaf
collimator (Siemens Medical, Germany) were used for the
radiotherapy. The beam energy was 6 MV for all patients.
A total dose of 30.0-60.0 Gy with a single fraction dose of
1.8 Gy (26 patients) and 2.0 Gy (5 patients) was prescribedto the PTV for both the IMRT and 3DCRT plan (Table 1).
For the evaluation of treatment plans tolerance doses for
the organs at risk as described by the Quantitative Analysis
of Normal Tissue Effects in the Clinic (QUANTEC) review
[2] were used.
Target volume definition
The target volumes were defined according to the Inter-
national Commission on Radiation Units and Measure-
ment (ICRU) Reports 50 and 62. The planning target
volume (PTV) included the gross tumor volume (GTV)
or preoperative GTV, draining nodal regions whenever in-
dicated, a margin of 5 mm to 10 mm for subclinical tumor
extension, a margin of 10 mm to 15 mm craniocaudally
and 5 mm transversely for organ motion, and a margin of
3 mm for patients positioning accuracy. The margins for
clinical extension and organ motion were adopted from
the literature [3,4] and the margins for the patient posi-
tioning accuracy derived from own measurements [5]. For
patients who received a PET/CT simulation the GTV was
defined in cooperation with an experienced nuclear medi-
cine physician by taking into account standardized uptake
values (SUV) and visual inspection of PET/CT images. No
oral contrast media, fluoroscopy or fiducial markers were
used to help to define target volumes or to account for
organ motion. Daily online verification using an electronic
portal imaging device was performed in all patients to
optimize the patient positioning accuracy.
The bowels were contoured as a whole-sum of the
gastrointestinal tract tube within 2 cm above and below
the craniocaudal extent of the PTV. The combined
volume of the right and left kidney was used for the
dose-volume histogram (DVH) analysis. The liver and
the scanned part of the spinal cord were contoured
entirely.
Inverse-planned intensity modulated radiotherapy (IMRT)
The normal tissue dose volume constraints used for the
IMRT plans are listed in Table 2. Tissue inhomogeneities
were considered in the treatment planning optimization
process, and the dose calculation algorithm used was
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applied, followed by a semiautomatic segmentation
(minimum 3 cm step size). Segments with less than ≤2
MU were expelled from the plan. A step-and-shoot tech-
nique was used with usually eight equally spaced copla-
nar fields. The number of segments of a typical plan was
around 70 and the corresponding treatment time about
10 minutes.
Three-dimensional conformal radiotherapy (3DCRT)
The dose was prescribed to the ICRU reference point
which was usually the isocenter located in the PTV vol-
ume centroid. A three to five coplanar beam technique,
multileaf collimator and virtual wedges were used for
the 3DCRT. The beam angles, virtual wedges, and beam
weighting were chosen to optimize coverage of the PTV,
while minimizing exposure to the organs at risk kidneys,
liver, bowel, stomach, and spinal cord.
Dose-volume histograms of the PTVs and organs at risk
of the IMRT and 3DCRT plans were generated and dose
parameters compared. The homogeneity index (HI) was
defined as the fraction of the PTV with a dose between
95% and 105% of the prescribed dose (V95% - V105%).
The conformity index (CI) was defined as the fraction of
the PTV surrounded by the reference dose (V95%) multi-
plied by the fraction of the total body volume covered byTable 3 Relevant plan parameters of IMRT versus 3DCRT of 3
IMRT 3DCRT
Parameter Mean SD Mean SD Mean
PTV
HI 0.97 0.03 0.96 0.04 −0.01
CI 0.71 0.20 0.65 0.23 −0.06
Combined kidneys
Mean dose (cGy) 1428 640 1322 656 −106
Maximum Dose (cGy) 3946 1418 4272 1130 325
V12 59.7 31.9 41.3 23.03 −18.4
V20 26.8 19.4 22.3 17.7 −4.5
V28 10.8 12.395 13.9 14.0 3.1
Liver
Mean dose (cGy) 1593 817 1427 890 −165
Maximum Dose (cGy) 4924 945 4592 1377 −332
Small bowel
Mean dose (cGy) 4394 1686 4237 1800 −157
V15 62.2 22.5 54.9 20.9 −7.3
Spinal cord
Maximum Dose (cGy) 2940 1003 2999 1208 59
IMRT = Reversed planned intensity modulated radiotherapy; 3DCRT = Three-dimens
RT = Definitive radiotherapy versus postoperative radiotherapy; † = ANOVA with re
x cGy isodose line; Plan = IMRT versus 3DCRT; Plan*Timing of RT = Interaction betwthe reference PTV dose ((PTV95%/PTV) × (PTV95%/
V95%)) [6].Statistics
IMRT and 3DCRT plan parameters derived from the same
patient were tested for statistically significant differences
using analysis of variance (ANOVA) for repeated mea-
surements. Parameters of the dose distribution were
entered as continuous variables in the ANOVA and the
timing of the radiotherapy (definitive radiotherapy versus
postoperative radiotherapy) as categorical variable. Differ-
ences were considered statistically significant if the two-
tailed p-value was less than or equal 0.05.Results
PTV
The diagnoses of the upper abdominal malignancies ex-
amined in this study are listed in Table 1. The ANOVA
for repeated measurements revealed that the conformity
index of the IMRT plans was significantly better com-
pared to the 3DCRT plans (p = 0.03) (Table 3). The homo-
geneity index was not significantly improved (p = 0.10).
The timing of the radiotherapy (definitive RT versus post-
operative RT) had no statistically significant impact on the
CI or HI.1 patients with upper abdominal tumors
Difference p-value†
−95CI +95CI Timing of RT Plan Plan*Timing of RT
−0.027 0.003 0.46 0.10 0.40
−0.109 −0.005 0.17 0.03 0.22
−256 44 0.01 0.16 0.46
58 593 0.06 0.02 0.23
−28.6 −8.3 0.13 <0.01 0.75
−8.63 −0.41 0.11 0.04 0.89
0.4 5.9 0.15 0.03 0.41
−261 −69 0.39 <0.01 0.34
−723 58 0.76 0.10 0.67
−556 242 0.27 0.39 0.15
−1.0 −4.6 0.67 <0.01 0.19
−269 386 0.83 0.72 0.89
ional planned conformal radiotherapy; CI = 95% confidence interval: Timing of
peated measurements; Vx = Percentage of tissue volume encompassed by the
een plan and timing of RT.
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For the combined kidneys, IMRT showed a significantly
reduced high dose volume (maximum dose and V28) on
cost of a significantly increased low dose volume (V20
and V12) (Table 3). No clinically relevant differences
were found for the liver, bowel and spinal cord. There
was no significant interaction between the timing of the
radiotherapy (definitive versus postoperative radiotherapy)
and the observed differences of the dose distribution
between IMRT and 3DCRT plans (Table 3).
Acute toxicity
A striking clinical observation was the low acute toxicity
of patients treated with IMRT. No patient developed
grade 3 or 4 non-hematological acute toxicity, and the
most common grade 2 toxicity was vomiting (9.7%)
(Table 4). The acute toxicity observed in our study
appears to be less than expected from patients treated
with 3DCRT. Reported non-hematological acute toxicities
grade 3 or higher of patients with pancreatic cancer
treated with definitive or postoperative radiochemotherapy
ranged from 10% to 19% [7-9]. However, comparison with
historical data has to be interpreted with great caution.
Discussion
Our dosimetric comparison showed a small but statisti-
cally significant improvement of the conformity index of
IMRT compared to 3DCRT plans for tumors located in
the upper abdomen. In addition, IMRT significantly
reduced the high-dose volume on cost of an increased
low-dose volume of the kidneys. A striking clinical ob-
servation of our study was the generally low acute tox-
icity of patients treated with IMRT. It can be speculated
that the low acute toxicity observed may be due to the
improved conformity index indicating a reduced high
dose volume around the tumor, and that in the upper
abdomen relatively small changes of the dose distribu-
tion may have a significant effect on the acute toxicity.
In agreement with our study, several other reports
described a more favourite dose distribution of IMRT
compared to 3DCRT for malignancies of the upper abdo-
men. Poppe et al. compared helical intensity-modulatedTable 4 Acute reactions of patients with upper abdominal
tumors treated with radiochemotherapy (n = 21) or
radiotherapy alone (n = 10)
Grade CTCAE v4
Adverse event 0 1 2 3–4
Nausea 51.6% 45.2% 3.2% 0%
Vomiting 80.6% 9.7% 9.7% 0%
Diarrhea 80.6% 19.4% 0.0% 0%
Weight loss 67.6% 29.0% 3.2% 0%
Abbreviation: CTCAE v4 common terminology criteria for adverse events
version 4.0.radiotherapy (HIMRT), linac-based IMRT and 3DCRT in
eight resected and eight unresected pancreatic cancer pa-
tients [4]. Both HIMRT and IMRT offered a statistically
significant improvement over 3DCRT in lowering the dose
to liver, stomach, and bowel. The results were similar for
both resected and unresected patients. Ringash et al.
assessed the potential advantage of IMRT over 3DCRT for
postoperative adjuvant radiotherapy in patients with gas-
tric carcinoma [10]. In 17 out of 19 (89%) patients the
IMRT plan was preferred over the corresponding 3DCRT
plan. The target coverage was improved, while spinal cord,
liver, kidney and heart dose was reduced in 69% to 74% of
the patients. Murthi et al. assessed the potential advantage
of IMRT over 3DCRT planning in postoperative adjuvant
radiotherapy for 15 patients with gastric carcinoma [11].
The IMRT plans achieved statistically significant better
target coverage with higher conformity index value com-
pared to 3DCRT plans. The doses to the liver and bowel
reduced significantly with IMRT plans compared to
3DCRT plans. For all organs at risk the percentage of
volumes receiving more than their tolerance doses were
reduced with the IMRT plans. Wieland et al. compared
IMRT, 3DCRT and anterior-posterior opposed (AP-PA)
beam arrangement in 15 gastric cancer patients to assess
the potential of IMRT to reduce radiation toxicity [12].
On average, median dose to the right kidney was the same
for the conventional box technique and IMRT but lower
for the AP-PA technique. In three patients, kidney dose
might have been ablative for both kidneys with both the
AP-PA technique and the box technique, whereas it was
acceptable with IMRT. The authors concluded that IMRT
can deliver efficient doses to target volumes while deliver-
ing dose to the kidneys in a fashion that is different from a
conventional technique and is clearly advantageous in a
small number of patients. A plan comparison study of 14
patients with gastric cancer by Alani et al. revealed a satis-
factory coverage of the PTV by the 95% isodose envelope
using either IMRT or 3DCRT [13]. However, IMRT was
only marginally better than 3DCRT at protecting the spine
and kidneys from radiation. The authors concluded that
IMRT confers only a marginal benefit in the adjuvant
treatment of gastric cancer and should be used only in the
small subset of patients with risk factors for kidney disease
or those with a preexisting nephropathy. In a dosimetric
study involving 10 patients with cancer of the distal
esophagus and gastrointestinal junction, target hetero-
geneity was improved in eight of ten patients by IMRT
compared to 3DCRT, and the conformity index improved
with the number of beams used for IMRT (4-beam versus
7-beam versus 9-beam IMRT) [14].
The impact of IMRT on acute gastrointestinal toxicity
was assessed in 46 patients with pancreatic and ampul-
lary cancer by Yovino et al. [15]. Compared to patients
treated with 3DCRT in the ROTG 97–04 trial the
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versus 11%, p = 0.024) and diarrhea (3% versus 18%,
p = 0.017) was significantly reduced. Similar observa-
tions of reduced gastrointestinal acute toxicity by
IMRT compared to published data of patients treated
with 3DCRT have been reported by several other
study groups [16-19].
Our study suggests that IMRT of malignancies of the
upper abdomen compared to 3DCRT offers a dosimetric
advantage and reduced acute toxicity. It should be noted
that we compared IMRT with 3-field or 5-field 3DCRT
plans and that more sophisticated 3DCRT plans may
yield more optimized dose distributions in selected pa-
tients. Furthermore, it should be stressed that the more
conformal dose distribution of IMRT may increase the
risk of geometrical miss and consequently the likelihood
of local failure.
Advances in diagnostic imaging, image-guided radio-
therapy as well as patient immobilization and organ
motion management throughout treatment planning and
treatment are required to optimize the radiotherapy of
upper abdominal malignancies [1,20-24]. Furthermore, a
better understanding of the partial volume tolerances of
the normal tissues is required to optimize the radiother-
apy treatment planning and to select the plan with the
best biologically effective dose distribution [1]. However,
a recent analysis of patterns of failure among 71 patients
treated with adjuvant IMRT for pancreas cancer sug-
gested that IMRT was not associated with an increase in
local recurrences [25].
In conclusion, IMRT of upper abdominal malignancies
offers the potential of a clinically relevant advantage of
the dose distribution compared to 3DCRT in terms of a
reduced acute toxicity. Further optimization of the
radiotherapy technique and more clinical trials are re-
quired before IMRT is routinely used for upper abdom-
inal malignancies.Abbreviations
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